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The Protein Kinase C bII (PKCbII) belongs to conven-
tional class of Protein kinase C enzyme and is preferen-
tially activated during diabetic cardiomyopathy [1]. An
effective inhibition of PKCbII is the potential option to
directly treat the diabetic cardiomyopathy. Till date only
one selective PKCbII inhibitor, ruboxistaurin reached
phase III clinical trial for diabetic complications. Thus,
there is an urgent need for exploring available chemical
space for new PKCbII inhibitors. The sequential virtual
screening workflow based on ligand and receptor based
query was followed to identify novel PKCbII inhibitors.
Three different strategies were followed for developing the
ligand based model by HipHop module implemented in
Catalyst, using: (I) three active and six moderately active
compounds; (II) 17 active compounds; (III) docked poses
of the compounds used in strategy (II). Receptor based
query was developed based on the cocrystallised crystal
structure of PKCbII with 2-methylbisindolylmaleimide
(2mBIM) using the Unity module of Sybyl7.1. The best
hypotheses from both methods consist of six features viz.
one hydrogen bond donor (D), two hydrogen bond accep-
tor (A), two hydrophobic-aromatic (HYD) and one ring
aromatic (R). Virtual screening scheme based on these 3D
hypotheses identified a few molecules with higher docking
score than the existing inhibitors. In addition, comparative
molecular dynamics (MD) simulation studies of uncom-
plexed PKCbII and its complexes with 2mBIM, ruboxis-
taurin and newly identified compounds were performed to
analyze the binding mode of the molecules. This study
showed that complexed form of PKCbII was more stable
than uncomplexed one during simulation period, and
showed the stable H-bond formation with Glu421, Val423.
This reveals the favorable interactions of identified com-
pounds with PKCbII.
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